ArticleFrontiers in oncology2026
Clinical diagnosis and treatment analysis of 11 cases of unicentric Castleman disease in the retroperitoneum.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Report of a case of renal hilum Castleman disease complicated with Paget's disease of the breast.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the diagnosis, treatment, and prognosis of unicentric Castleman disease (UCD) located in the retroperitoneum. Methods: A retrospective analysis was conducted on the clinical data of 11 patients with pathologically confirmed retroperitoneal UCD at Peking University People's Hospital between 2010 and 2025. Data collected included gender, age, clinical manifestations, routine blood tests, tumor markers, treatment modalities, pathological characteristics, and treatment outcomes. Postoperative survival status was assessed via outpatient records and telephone follow-up. Results: The cohort comprised 3 males and 8 females. One male patient had a history of long-term smoking and alcohol use, while the other 10 patients had no such history. One patient presented with lower back discomfort, one with abdominal discomfort, and the remaining 9 patients were incidentally diagnosed during health check-ups. All patients had serum inflammatory markers and tumor markers within normal ranges. Preoperative abdominal contrast-enhanced CT/MRI localized the lesions in all cases. The mean maximum tumor diameter was 5.23 ± 2.05 cm. Five patients underwent laparoscopic surgery, and six underwent open surgery. The mean operative time was 2.73 ± 1.21 hours, with an intraoperative blood loss of 100 ml (IQR 20-100 ml). No severe postoperative complications occurred. The mean hospital stay was 5.00 ± 1.79 days, and all patients recovered well and were discharged. Pathological examination revealed the hyaline vascular type in 9 cases, the plasma cell type in 1 case, and the mixed type in 1 case. The mean follow-up duration was 68.00 ± 30.41 months (range: 25-112 months). By the end of follow-up, no recurrence was observed, and all patients remained alive and healthy. Conclusion: Retroperitoneal unicentric Castleman disease is rare and lacks specific clinical manifestations. Complete surgical resection is the optimal treatment, and patients exhibit excellent long-term prognosis upon follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.